It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Applied Genetic Technologies Corp (AGTC) USD0.001

Sell:$3.75 Buy:$3.92 Change: $0.21 (5.72%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Change: $0.21 (5.72%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Change: $0.21 (5.72%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Contact details

14193 Nw 119Th Terrace, Suite #10
United States
+1 (386) 4622204

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$160.39 million
Shares in issue:
42.66 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Scott Koenig
    Independent Chairman of the Board
  • Susan Washer
    President, Chief Executive Officer, Director
  • William Sullivan
    Chief Financial Officer
  • Matthew Feinsod
    Executive Vice President - Global Strategy and Development
  • Stephen Potter
    Vice President and Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.